Co-delivery of micellar Berberine and Doxorubicin protected cardiomyocytes against doxorubicin toxicity (CI > 1) while synergistically enhancing cytotoxicity in ovarian cancer cells (CI < 1).
Does co-delivery of micellar berberine and doxorubicin protect against doxorubicin-induced cardiotoxicity in cardiomyocytes while maintaining anticancer efficacy in ovarian cancer cells?
Micellar berberine protects cardiomyocytes from doxorubicin toxicity while synergistically enhancing its anticancer efficacy in ovarian cancer cells in vitro.
Abstract Background: Berberine (Ber) has free radical scavenging abilities and potential chemosensitizing effects. Doxorubicin (Dox) is a highly effective chemotherapeutic agent that is associated with significant cardiotoxicity. We hypothesize that Ber could be loaded into Pluronic F127® micelles (mBer), leading to an improvement in Ber activity. Objectives: The objective of this study was to evaluate the potential of Ber in protecting cultured cardiomyocytes against doxorubicin-induced cardiotoxicity (DIC) while concurrently examining its chemosensitizing influence when administered in conjunction with Dox to cultured ovarian adenocarcinoma cells. Materials and Methods: The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay was used to detect cell viability in cardiomyocytes (H9c2) and ovarian cancer cells (SKOV-3) with either Ber or mBer alone or in combination with Dox. Combination index (CI) analyses were also conducted in order to ascertain the effects of the combinations. Results: In H9c2 cells, co-delivery of mBer and Dox resulted in a significantly higher IC50 than Dox alone, and they showed an antagonistic effect in combination (CI > 1). When Ber is incorporated into the F127 micelle, its cardioprotective activity is enhanced. Conversely, the reduction in cell viability and the CI values (CI < 1) showed that this combination was synergistic in SKOV-3, indicating the chemosensitizing effect of mBer. Conclusions: The co-administration of mBer and Dox has demonstrated cardioprotective effects against DIC and may hold promise as a prospective therapeutic approach for cancer.
Alyasari et al. (Thu,) conducted a other in Doxorubicin-induced cardiotoxicity and ovarian adenocarcinoma. Micellar Berberine (mBer) and Doxorubicin (Dox) vs. Doxorubicin alone or Berberine alone was evaluated on Cell viability and Combination index (CI). Co-delivery of micellar Berberine and Doxorubicin protected cardiomyocytes against doxorubicin toxicity (CI > 1) while synergistically enhancing cytotoxicity in ovarian cancer cells (CI < 1).